Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Plunkett Research, Ltd.
$99.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Eli Lilly And Co's PRONOUNCE Study Does Not Achieve Primary Superiority Endpoint For ALIMTA


Monday, 3 Jun 2013 08:00am EDT 

Eli Lilly And Co announced that results from PRONOUNCE trial of ALIMTA (pemetrexed for injection) for treatment of nonsquamous non-small cell lung cancer (NSCLC) that was presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Ill. The PRONOUNCE trial compared an ALIMTA (pemetrexed), carboplatin doublet regimen to a paclitaxel, carboplatin and bevacizumab triplet regimen. The study did not achieve primary superiority endpoint of improved progression-free survival without grade four adverse events (G4PFS). No significant difference was observed between the treatment arms for secondary endpoints of progression-free survival (PFS), overall survival, overall response rate and disease control rate. Toxicity profiles observed in the trial were consistent with the known safety profiles of each therapy. 

Company Quote

47.6
0.765 +1.63%
10:45am EDT